These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24559843)

  • 1. Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
    Huffman KM; Sun JL; Thomas L; Bales CW; Califf RM; Yates T; Davies MJ; Holman RR; McMurray JJ; Bethel MA; Tuomilehto J; Haffner SM; Kraus WE
    Metabolism; 2014 Apr; 63(4):554-61. PubMed ID: 24559843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
    Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
    Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
    Scheen AJ
    Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Preiss D; Giles TD; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Mazzone T; Rutten GE; Tognoni G; Chiang FT; McMurray JJ; Califf RM
    Stroke; 2013 Sep; 44(9):2590-3. PubMed ID: 23899915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Latini R; Staszewsky L; Sun JL; Bethel MA; Disertori M; Haffner SM; Holman RR; Chang F; Giles TD; Maggioni AP; Rutten GE; Standl E; Thomas L; Tognoni G; Califf RM; McMurray JJ
    Am Heart J; 2013 Nov; 166(5):935-40.e1. PubMed ID: 24176451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
    Chatterjee R; Thomas L; Svetkey L; Brancati FL; Califf RM; Edelman D
    Am J Hypertens; 2013 Jun; 26(6):723-6. PubMed ID: 23417031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
    Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
    Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
    ; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
    N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of valsartan on the incidence of diabetes and cardiovascular events.
    ; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
    N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.
    Katz M; Califf RM; Sun JL; McMurray JJ; Thomas L; Lopes RD
    Am J Med; 2015 Mar; 128(3):297-302. PubMed ID: 25447626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
    Shen L; Shah BR; Reyes EM; Thomas L; Wojdyla D; Diem P; Leiter LA; Charbonnel B; Mareev V; Horton ES; Haffner SM; Soska V; Holman R; Bethel MA; Schaper F; Sun JL; McMurray JJ; Califf RM; Krum H
    BMJ; 2013 Dec; 347():f6745. PubMed ID: 24322398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
    Preiss D; Thomas LE; Wojdyla DM; Haffner SM; Gill JM; Yates T; Davies MJ; Holman RR; McMurray JJ; Califf RM; Kraus WE;
    BMJ Open; 2015 Aug; 5(8):e007901. PubMed ID: 26275900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navigating the choices for diabetes prevention.
    Nathan DM
    N Engl J Med; 2010 Apr; 362(16):1533-5. PubMed ID: 20228400
    [No Abstract]   [Full Text] [Related]  

  • 18. Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.
    Nash DT; Crikelair N; Zappe D
    Curr Med Res Opin; 2008 Sep; 24(9):2617-26. PubMed ID: 18687165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.